title: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group.
abstract: This double-blind randomised phase III trial was designed to assess the effect of pyridoxine administration on the recurrence of Ta and T1 transitional cell tumours of the bladder. The trial accrued 291 patients and showed no significant difference between the pyridoxine and placebo treatment groups with respect to the time to first recurrence or the recurrence rate. Adjustment for the main prognostic factors, namely the recurrence rate prior to entry, the number of tumours at entry, the G grade and the levels of the tryptophan metabolites kynurenine plus acetyl kynurenine at entry do not change the overall conclusions.
authors.affiliation: Free University Hospital, Department of Urology, Amsterdam, The Netherlands.
authors.forename: D W
authors.initials: DW
authors.lastname: Newling
authors.forename: M R
authors.initials: MR
authors.lastname: Robinson
authors.forename: P H
authors.initials: PH
authors.lastname: Smith
authors.forename: D
authors.initials: D
authors.lastname: Byar
authors.forename: R
authors.initials: R
authors.lastname: Lockwood
authors.forename: I
authors.initials: I
authors.lastname: Stevens
authors.forename: M
authors.initials: M
authors.lastname: De Pauw
authors.forename: R
authors.initials: R
authors.lastname: Sylvester
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000517:prevention & control / Q000652:urine; D004311:Double-Blind Method; D005060:Europe; D005260:Female; D006801:Humans; D007736:Kynurenic Acid / Q000652:urine; D007737:Kynurenine / Q000652:urine; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control* / Q000652:urine; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011736:Pyridoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D014364:Tryptophan / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000517:prevention & control / Q000652:urine; D014977:Xanthurenates / Q000652:urine
chemical_list: D000970:Antineoplastic Agents; D014977:Xanthurenates; D007737:Kynurenine; C028330:xanthurenic acid; D014364:Tryptophan; D007736:Kynurenic Acid; D011736:Pyridoxine